Clinico-pathologic features | HER2-positive cases (n = 43) | p-value | HER2-negative cases (n = 461) | p-value | ||
---|---|---|---|---|---|---|
Both p-smad2 and c-Met positive (n = 13) | Either p-smad2 or c-Met negative (n = 30) | Both p-smad2 and c-Met positive (n = 79) | Either p-smad2 or c-Met negative (n = 382) | |||
Age | ||||||
  < 60 | 4 (33.3%) | 8 (66.7%) | 22 (16.1%) | 115 (83.9%) | ||
 ≧60 | 9 (29.0%) | 22 (71.0%) | 1.000 | 57 (17.6%) | 267 (82.4%) | 0.690 |
Macroscopic type | ||||||
 Bormann type 4 | 1 (50%) | 1 (50%) | 7 (13.2%) | 46 (86.8%) | ||
 Other types | 12 (29.3%) | 29 (70.7%) | 0.518 | 72 (17.7%) | 336 (82.3%) | 0.420 |
Microscopic type | ||||||
 Differentiated | 11 (32.4%) | 23 (67.6%) | 48 (22.3%) | 167 (77.7%) | ||
  Well differentiated | 2 | 7 | 12 | 54 | ||
  Moderately differentiated | 8 | 16 | 33 | 111 | ||
  Papillary | 1 | 0 | 3 | 2 | ||
 Undifferentiated | 2 (22.2%) | 7 (77.8%) | 0.699 | 31 (12.6%) | 215 (87.4%) | 0.006 |
  Poorly differentiated | 1 | 6 | 22 | 143 | ||
  Signet-ring cell | 0 | 1 | 7 | 62 | ||
  Mucinous | 1 | 0 | 2 | 7 | ||
  Small cell | 0 | 0 | 0 | 3 | ||
T stage | ||||||
 T1/T2 | 5 (20%) | 20 (80%) | 40 (15.7%) | 215 (84.3%) | ||
 T3/T4 | 8 (44.4%) | 10 (55.6%) | 0.104 | 39 (18.9%) | 167 (81.1%) | 0.358 |
Lymph node metastasis | ||||||
 Negative | 3 (15.8%) | 16 (84.2%) | 37 (14.5%) | 218 (85.5%) | ||
 Positive | 10 (41.7%) | 14 (58.3%) | 0.098 | 32 (20.4%) | 164 (79.6%) | 0.096 |
Metastasis | ||||||
 Negative | 12 (28.6%) | 30 (71.4%) | 78 (17.4%) | 371 (82.6%) | ||
 Positive | 1 (100%) | 0 (0%) | 0.302 | 1 (8.3%) | 11 (91.7%) | 0.700 |
Pathological stage | ||||||
 I/II | 5 (18.5%) | 22 (81.5%) | 50 (17.0%) | 245 (83.0%) | ||
 III/IV | 8 (50%) | 8 (50%) | 0.042 | 29 (17.5%) | 137 (82.5%) | 0.887 |